N/A N=94 Natural History of Chronic Urticaria
Chronic Urticaria
Primary: Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. — 18.5; 54; 67.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 2 N=31 Cold Urticaria Treatment With Xolair
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
Early Phase 1 N=10 Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants
Phase 4 N=18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
Phase 4 N=314 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
Chronic Idiopathic Urticaria
Primary: Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg — -1.0; -1.0; -1.1; 2.9 Units on a scale…
Phase 4 N=886 CUTE (Chronic Urticaria Treatment Evaluation)
Chronic Idiopathic Urticaria
Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001
Phase 2 N=28 Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
Chronic Idiopathic Urticaria
Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores
Phase 2 N=49 Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Chronic Urticaria
Primary: Change in the Weekly Urticaria Activity Score (UAS7) From Baseline to the End of the Study (Week 24) — -17.8; -5.8 Units on a scale
Phase 2 N=90 A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Chronic Idiopathic Urticaria
Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601
N/A N=42 The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
Urticaria · Angioedema · Hives
Primary: Medication Usage — 2.8; 4.6; 2.0; 4.9 number of pills/day
Phase 4 N=10 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Chronic Urticaria
Primary: Change in the Basophil Proteome — 4; 0; 3 Participants
Phase 4 N=136 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
CHRONIC SPONTANEOUS URTICARIA
Primary: Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12 — 75.0 percent of participants
Phase 3 N=336 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Chronic Idiopathic Urticaria
Primary: Percentage of Participants With Adverse Events — 78.3; 83.7 Percentage of participants
Phase 2 N=183 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 — -13.6; -18.4; -13.5; -14.7 score on a scale — p=0.99
Phase 2 N=134 A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 — -19.16; -24.05; -11.25; -15.69 Score on a Scale — p=0.0559
Phase 2 N=4 Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
Urticaria
Primary: Number of Participants With Adverse Events — 3 participants
Phase 3 N=319 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Chronic Idiopathic Urticaria
Primary: Change From Baseline to Week 12 in the Weekly Itch Severity Score — -3.63; -6.46; -6.66; -9.40 Units on a scale — p=0.0010
Phase 3 N=418 Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment — -10.11; -9.66; -5.87 Score on a scale — p=<0.001
Phase 4 N=205 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
Urticaria
Primary: Percentage of Participants Who Experienced Clinical Worsening in CIU as Assessed by Urticaria Activity Score Over 7 Days (UAS7) (Clinical Worsening: UAS7 Greater Than or…
Phase 3 N=323 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Chronic Idiopathic Urticaria
Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -5.14; -5.87; -8.14; -9.77 Units on a scale — p=0.4637
Phase 3 N=608 Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Chronic Urticaria
Primary: Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission) — -10.92; -10.61 units on…
N/A N=166 The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Chronic Urticaria
Primary: Cross-Cultural Validity of Thai-version CU-Q2oL — 43.71; 22.11; 9.41; 20.21 Percentage — p=<0.01
Phase 3 N=82 Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Cold Urticaria
Primary: Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 — 37.5; 40.5 percentage of participants — p=0.9492
Phase 2 N=40 Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Chronic Idiopathic Urticaria
Primary: Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin — 18.14; 15.17; 13.40; 20.19 FcεRI positive skin…
Phase 2 N=10 Omalizumab in Severe and Refractory Solar Urticaria
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
Phase 3 N=218 Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
Chronic Spontaneous Uriticaria
Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -10.22; -8.80; -6.51 Units on a scale — p=<0.001
Phase 2 N=49 Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous Urticaria
Primary: Change From Baseline of Weekly Urticaria Activity Score (UAS7) at Week 24 — -20.36; -22.50; -21.26 Score on a scale
Phase 2 N=30 A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Chronic Inducible Urticaria
Primary: Safety and Tolerability — 3; 7 Participants with a TEAE
Phase 2 N=226 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Chronic Spontaneous Urticaria
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (AE) — 190 Participants